New research has revealed that mixing rapid-acting and long-acting insulin in the same syringe is safe and will not compromise long-term control of blood sugar levels.
The study, published in the Journal of Paediatrics and carried out at the University of Colorado in Denver, has far-reaching lifestyle implications for type 1 diabetics and type 2 diabetics who have to use insulin to control their disease.
In theory therefore, rapid-acting insulin analogues (such as NovoRapid) could be combined in the same syringe as long-acting insulin glargine (Lantus) decreasing the number of daily injections necessary to control blood sugar levels.
To obtain the results, the researchers compared the blood sugar levels of 55 children who mixed rapid-acting analog with long-acting glargine, with 55 children who used separate injections. The study team compared blood sugar control over a six month period, and found that the two groups were very similar.
The experts at the helm of the study concluded: “The findings are especially encouraging to those patients who wish to minimize the number of total daily injections because of needle fear, forgetting injections, or other injection-related issues.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…